Author:
Parham Groesbeck P.,Egemen Didem,Befano Brian,Mwanahamuntu Mulindi H.,Rodriguez Ana Cecilia,Antani Sameer,Chisele Samson,Munalula Mukatimui Kalima,Kaunga Friday,Musonda Francis,Malyangu Evans,Shibemba Aaron Lunda,de Sanjose Silvia,Schiffman Mark,Sahasrabuddhe Vikrant V.
Abstract
Abstract
Background
WHO has recommended HPV testing for cervical screening where it is practical and affordable. If used, it is important to both clarify and implement the clinical management of positive results. We estimated the performance in Lusaka, Zambia of a novel screening/triage approach combining HPV typing with visual assessment assisted by a deep-learning approach called automated visual evaluation (AVE).
Methods
In this well-established cervical cancer screening program nested inside public sector primary care health facilities, experienced nurses examined women with high-quality digital cameras; the magnified illuminated images permit inspection of the surface morphology of the cervix and expert telemedicine quality assurance. Emphasizing sensitive criteria to avoid missing precancer/cancer, ~ 25% of women screen positive, reflecting partly the high HIV prevalence. Visual screen-positive women are treated in the same visit by trained nurses using either ablation (~ 60%) or LLETZ excision, or referred for LLETZ or more extensive surgery as needed. We added research elements (which did not influence clinical care) including collection of HPV specimens for testing and typing with BD Onclarity™ with a five channel output (HPV16, HPV18/45, HPV31/33/52/58, HPV35/39/51/56/59/66/68, human DNA control), and collection of triplicate cervical images with a Samsung Galaxy J8 smartphone camera™ that were analyzed using AVE, an AI-based algorithm pre-trained on a large NCI cervical image archive. The four HPV groups and three AVE classes were crossed to create a 12-level risk scale, ranking participants in order of predicted risk of precancer. We evaluated the risk scale and assessed how well it predicted the observed diagnosis of precancer/cancer.
Results
HPV type, AVE classification, and the 12-level risk scale all were strongly associated with degree of histologic outcome. The AVE classification showed good reproducibility between replicates, and added finer predictive accuracy to each HPV type group. Women living with HIV had higher prevalence of precancer/cancer; the HPV-AVE risk categories strongly predicted diagnostic findings in these women as well.
Conclusions
These results support the theoretical efficacy of HPV-AVE-based risk estimation for cervical screening. If HPV testing can be made affordable, cost-effective and point of care, this risk-based approach could be one management option for HPV-positive women.
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Infectious Diseases,Oncology,Epidemiology
Reference31 articles.
1. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, 2nd edn; 2021.
2. WHO. One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer; 2022. Accessed Oct 10 2022. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer.
3. Perkins RB, Smith DL, Jeronimo J, et al. Use of risk-based cervical screening programs in resource-limited settings. Cancer Epidemiol. 2023;84:102369. https://doi.org/10.1016/j.canep.2023.102369.
4. Desai KT, Ajenifuja KO, Banjo A, et al. Design and feasibility of a novel program of cervical screening in Nigeria: self-sampled HPV testing paired with visual triage. Infect Agent Cancer. 2020;15:60. https://doi.org/10.1186/s13027-020-00324-5.
5. Desai KT, Adepiti CA, Schiffman M, et al. Redesign of a rapid, low-cost HPV typing assay to support risk-based cervical screening and management. Int J Cancer. 2022;151(7):1142–9. https://doi.org/10.1002/ijc.34151.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献